Pharmacologic inhibition of RAS/MAPK signaling with rigosertib suppresses HCC cell proliferation and induces apoptosis, accompanied by marked decreases in ERK phosphorylation [111,112]. The gene discussed is MAPK1; the disease is hepatocellular carcinoma.